Breast cancer is a malignancy with the highest incidence and mortality rate among women in the world. The current treatment methods include surgery, chemotherapy, radiotherapy, endocrine therapy and targeted therapy. Triple negative breast cancer (TNBC) has high manignant behavior and poor prognosis, lacks specific treatment targets, thus resulting in few effective treatment modalities. The emergence of immunotherapy has provided hopes for TNBC. The efficacy of immunocheckpoint inhibitors in neoadjuvant treatment of early TNBC and first-line treatment of programmed death-ligand 1 positive metastatic TNBC. Therefore, this article reviews the researches of immunocheckpoint inhibitors in the treatment of early and advanced breast cancer.
During the coronavirus disease 2019 epidemic, West China Hospital, Sichuan University explored a new management model to ensure timely diagnosis and treatment and regular follow-up for breast cancer patients. On the basis of previous internet Breast Cancer Information Management System, patient management WeChat groups were integrated to develop an online and offline interconnect management platform. Regular follow-up of patients was mainly conducted by telephone, with WeChat management group as auxiliary. Coronavirus infections were screened during telephone follow-up. In the meanwhile, patients who needed to be further treated would be identified and recommended to the outpatient follow-up. The new management model can improve the efficiency of follow-up management, on the premise of reducing the risk of coronavirus disease 2019 transmission for both health care providers and patients.